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The envelope glycoproteins El and E2 of rubella virus were abundantly expressed in Spodoptera frugiperda
Sf9 insect cells by using a baculovirus expression vector. The recombinant protein products were purified by
immunoaffinity chromatography and characterized by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis, immunoblotting, and enzyme immunoassay (EIA). The purified recombinant antigen consisted of the
envelope polypeptides, corresponding to the viral El and E2 proteins, and a polyprotein precursor (molecular
mass, 90 to 95 kDa). The antigen was reactive with human convalescent-phase sera in immunoblot analysis, and
the reactivity correlated well (r = 0.861) with that of a whole-virus antigen when tested by EIA by using a total
of 106 rubella virus immunoglobulin G-positive and -negative serum specimens. When the sera from patients
with recent rubella virus infection were tested with the recombinant glycoproteins by EIA, the correlation was
not as close (r = 0.690). However, all of the 26 serum specimens were reactive with the recombinant antigen.
The results demonstrate that these bioengineered antigens have a potential for use in routine diagnostic assays
of rubella virus immunity and recent infection.
Rubella virus (RV) is an enveloped, positive-stranded
RNA virus that belongs to the family Togaviridae (22).
Rubella is normally a mild, self-limited disease, but it may
cause fetal damage if it is acquired during the first trimester
of pregnancy. Thus, serological tests to determine the im-
mune status in women of childbearing age and tests to
diagnose recent RV infections in pregnant women are of
great importance.
RV consists of three structural proteins: a nonglycosy-
lated capsid protein, C (molecular mass, 33 kDa), and two
envelope glycoproteins, El (molecular mass, 58 kDa) and E2
(molecular mass, 42 to 47 kDa) (19, 28, 30). The hemagglu-
tination activity (9, 24, 30) and a major epitope with viral
neutralization activity (9, 24, 31) have been localized to the
El protein. El has been shown to contain at least six
antigenic epitopes (5, 31), and it has been demonstrated that
the antigenicity of the El protein is independent of its
glycosylation (8). The E2 glycoprotein has not been as well
characterized, and the difficulties in generating anti-E2
monoclonal antibodies suggest that immunogenicity of the
E2 protein is poor or that the epitopes may be hidden under
the El protein in the envelope spike complexes (8). How-
ever, it has also been demonstrated that the E2 protein
contains a neutralization epitope (5). The natural antibody
response to El is predominant in most patients with RV
infections, but in patients with the congenital rubella syn-
drome, the antibodies to E2 were found to be more abundant
(11).
Baby hamster kidney cells (BHK-21) (29) or African green
monkey kidney (Vero) cells (1) are used in the conventional
methods of growing RV. However, by those methods, the
yield of virus remains low, despite the improvements in the
cell culture systems for large-scale production (26). Alterna-
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tive approaches for the production of RV antigens in vitro
have been presented. The bioengineered structural proteins
of RV have been produced by genetic expression in Esche-
richia coli (25) or by using simian virus 40 (3, 18) or pCMV5
(7) expression vectors in COS cells. The possibility of using
the synthetic peptides as antigens in serological tests has
also been studied (14).
Baculovirus expression vectors, which use the polyhedrin
promoter of the Autographa californica nuclear polyhedro-
sis virus (AcNPV), have been used for the expression of
foreign procaryotic or eucaryotic genes. The recombinant
genes are expressed as fusion or nonfusion proteins during
viral infection, and most recombinant protein products ap-
pear to undergo normal posttranslational modifications (15,
16).
We have previously shown (20) that the El and E2
proteins expressed in Spodopterafrugiperda Sf9 insect cells,
using a baculovirus expression vector, reacted with human
rubella antibodies. We therefore expressed the correspond-
ing El and E2 proteins of RV, using a baculovirus expres-
sion vector construct, to study whether these recombinant
protein products can be used in the diagnosis of RV infec-
tion.
MATERIALS AND METHODS
Sera. A total of 106 serum specimens were examined for
RV immunoglobulin G (IgG) antibodies by using recombi-
nant RV enzyme immunoassay (EIA) and RV EIA test kits.
Sera were obtained from randomly selected healthy blood
donors (The Finnish Red Cross Blood Transfusion Service);
over 90% of the serum specimens were statistically known to
have RV IgG antibodies. RV IgG antibody-negative sera
were obtained from Boston Biomedica Inc. (Mansfield,
Mass.). In addition, 26 serum specimens from patients
diagnosed to have recent RV infection (Department of
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Virology, University of Helsinki, Helsinki, Finland) were
tested.
Cells and virus. S. frugiperda Sf9 cells were propagated as
monolayer cultures at 27°C in TNMFH medium supple-
mented with 10% (vol/vol) heat-inactivated fetal bovine
serum (Flow Laboratories, Irvine, Calif.), as described
previously (20). A recombinant baculovirus (Ac701-RVE)
containing the E2-E1-coding region of RV, including the
sequence encoding the E2 signal peptide, was used. The
recombinant proteins were expressed in infected cells under
the transcriptional regulation of the polyhedrin gene pro-
moter (20).
The Therien strain of RV grown in B-Vero cell cultures
was purified as described previously (19) and was used as the
reference antigen in immunoblotting experiments.
Purification of the recombinant proteins. At 48 to 72 h
postinfection, cells were pelleted by low-speed centrifuga-
tion (400 x g, 2 min), washed twice with phosphate-buffered
saline (PBS; 10 mM sodium phosphate, 0.9% NaCl [pH 7.4]),
and resuspended in TNE buffer (10 mM Tris hydrochloride,
0.15 M NaCl, 1 mM EDTA [pH 7.8]) containing 1% Nonidet
P-40 and 0.2 mM phenylmethylsulfonyl fluoride. After son-
ication, the sample was clarified by centrifugation (5,000 x
g, 5 min) and applied to an immunoaffinity column contain-
ing rabbit anti-RV IgG antibodies (10 mg, protein A purified)
linked to Sepharose 4B (Pharmacia, Uppsala, Sweden). The
recombinant proteins were incubated overnight at 4°C with
the affinity matrix, and the unbound proteins were washed
with TNE buffer. The recombinant proteins were eluted with
50 mM lithium diiodosalicylate (pH 8.0; elution rate, 36
ml/h). The fractions, 1 ml each, were collected, diluted (1:10)
with PBS, and tested by EIA as described below. The
immunoreactive fractions were pooled and concentrated
(Centricon microconcentrators; Amicon, Danvers, Mass.).
Sodium dodecyl sulfate (SDS)-PAGE and immunoblotting.
Wild-type baculovirus (AcNPV strain E2)-infected S. fru-
giperda Sf9 cells, recombinant virus (Ac701-RVE)-infected
Sf9 cells, purified recombinant proteins, and purified RV
were separated under reducing or nonreducing conditions by
polyacrylamide gel electrophoresis (PAGE; 10% [wt/vol]),
as described by Laemmli (13), transferred to a nitrocellulose
sheet (27), and tested for their immunoreactivities as de-
scribed previously (21). The human and rabbit sera were
used at dilutions of 1:50.
Whole-virus EIA. RV IgG and IgM antibodies were mea-
sured with RV EIA test kits (Rubella IgG EIA and Rubella
IgM EIA; Labsystems, Helsinki, Finland).
Recombinant RV EIA. Microtitration wells (Labsystems)
were coated with purified recombinant RV antigen (100 [lI
per well) at 4°C overnight. Test sera were diluted 1:50 with
PBS containing 1% bovine serum albumin and Tween 20 and
incubated for 1 h at 37°C in recombinant RV antigen-coated
wells. Unbound proteins were removed by rinsing the wells
three times with a PBS-Tween 20 washing solution. RV-
specific IgG antibodies were detected by incubation for 1 h at
37°C with alkaline phosphatase-conjugated anti-human IgG
antibodies (Labsystems). The quantity of bound enzyme
conjugate was measured by incubation with the substrate
p-nitrophenylphosphate. The enzyme reaction was stopped
after 30 min with 1 M NaOH, and the amount of bound
RV-specific IgG antibodies was determined by measuring
the A405 (Multiscan MC; Labsystems). A reagent blank and
negative and positive controls were included in each test
run. The results were expressed as ElUs (for the definition
of EIUs, see the legend to Fig. 4).
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FIG. 1. SDS-PAGE analysis of the recombinant RV antigen
produced in baculovirus-infected S. frugiperda Sf9 cells. Lane 1,
molecular weight markers (in thousands; K); lane 2, purified RV;
lane 3, AcNPV (wild-type virus, strain E2)-infected Sf9 cells; lane 4,
Ac7Ol-RVE (recombinant virus)-infected Sf9 cells; lane 5, immu-
noaffinity-purified recombinant RV antigen. The proteins corre-
sponding to the viral El and E2 proteins are indicated.
RESULTS
Purification of recombinant RV glycoproteins. The recom-
binant RV proteins were purified by immunoaffinity chroma-
tography by using rabbit anti-RV antibodies. The antigenic
activities of the proteins were found to remain intact when
the elution was done with 0.05 M lithium diiodosalicylate, as
has also been demonstrated for purification of whole-virus
antigen (2) and for purification of bioengineered El protein
(25). The recovery of the purification could not be detected
by measuring the A280 because of the presence of lithium
diiodosalicylate. The fractions were tested by EIA by using
RV-negative and -positive sera, and the fractions showing
good responses with positive samples and low reactivities
with negative samples were pooled and concentrated. This
antigen was then analyzed by SDS-PAGE (Fig. 1).
The purified recombinant proteins El and E2 (Fig. 1, lane
5) migrated somewhat faster than those derived from purified
RV did (Fig. 1, lane 2). This is most likely due to differences
in glycosylation between the two systems, as has been
suggested previously (20). Cellular extracts of S. frugiperda
Sf9 cells infected with wild-type (AcNPV) as well as recom-
binant (Ac7O01-RVE) baculoviruses before purification are
shown in Fig. 1, lanes 3 and 4, respectively. The recombi-
nant proteins could hardly be identified from cellular ex-
tracts before purification.
Identification of the purified recombinant proteins. The
identities of the recombinant polypeptides were further
established by immunoblot analysis by using rabbit anti-RV
antibodies (Fig. 2). From extracts of whole S. frugiperda Sf9
cells infected with the recombinant baculovirus, the El
protein as well as a few minor additional proteins could be
seen (Fig. 2, lane 3). In lane 4 of Fig. 2, which represents the
purified recombinant antigen, the polyprotein precursor and
the El and E2 proteins were clearly identified. In addition, a
protein migrating somewhat slower than El, which was also
present in wild-type baculovirus-infected cells (Fig. 2, lane
2) and recombinant baculovirus-infected cells (Fig. 2, lane
3), was seen.
Figure 3 shows the reactivities of human RV IgG-positive
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FIG. 2. Immunoblot analysis of nonreduced recombinant RV
antigen by using rabbit anti-RV antibodies. Lane 1, purified RV;
lane 2, AcNPV (wild-type virus, strain E2)-infected S. frugiperda
Sf9 cells; lane 3, recombinant RV-infected Sf9 cells; lane 4, purified
recombinant RV antigen. The proteins corresponding to the viral El
and E2 proteins and the polyprotein precursor are shown.
sera with purified recombinant antigen in immunoblot anal-
ysis. These sera were reactive with the El protein, while the
IgG-negative serum did not show any reactivity.
Recombinant proteins in EIA. The antigenic properties of
recombinant El and E2 proteins were finally evaluated by
EIA. Figure 4 shows the correlation of the reactivities ofRV
IgG antibody-positive and -negative sera between recombi-
nant RV and whole-virus antigen by using a total of 106
serum samples. The reactivities of these two different anti-
gens correlated with a coefficient of r = 0.861.
IgG antibodies of some serum specimens from cases of
recent RV infection reacted strongly with the capsid protein
(C) (Fig. 5), which was not expressed in our recombinant
system. Because of these differences in IgG reactivities, the
panel of 26 serum specimens from patients with recent RV
infection was tested. Figure 6 shows the correlation of the
reactivities of the IgG antibodies between recombinant RV
and whole-virus antigen by using these sera, which were
tested earlier and shown to contain RV IgM antibodies. All
of the corresponding sera were positive with the recombi-
nant antigen, although some variability in reactions (r =
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FIG. 3. Immunoblot analysis of nonreduced purified recombi-
nant RV antigen with human serum samples. Lane 1, molecular
weight markers (in thousands; K); lane 2, reactivity of an RV-
negative serum sample; lanes 3 to 5, reactivities of different RV IgG
antibody-positive sera. The protein corresponding to the viral El
protein is shown.
0.690) could be seen, when they were compared with the
whole-virus antigen.
DISCUSSION
In the present study, we abundantly expressed the El and
E2 envelope glycoproteins of RV in recombinant baculovi-
rus (Ac70l-RVE)-infected S. frugiperda Sf9 cells and exam-
ined the immunological characteristics of this antigen when
it was purified by immunoblotting and EIA.
The recombinant antigen (Fig. 1, lane 5) contained, after
staining with Coomassie blue, a diffuse band that migrated
somewhat faster than the authentic El protein (58 kDa) of
RV did. Also, a band corresponding to the E2 protein of RV
was shown to migrate faster than authentic E2 protein (42 to
47 kDa). This is in agreement with the earlier findings of
Oker-Blom et al. (20) and is believed to be caused by
differences in glycosylation between Sf9 and vertebrate
cells, as has also been demonstrated in a recent study in
which the influenza virus hemagglutinin was expressed (12).
In addition, the antigen contained a protein which could be
seen as a band above the El protein. This protein is most
likely the same cellular protein which exists in whole-virus
preparations and may be captured by the rabbit anti-RV
antibodies with recombinant antigen in immunoaffinity chro-
matography.
Recombinant polypeptides were identified by immuno-
blotting by using rabbit anti-RV antibodies (Fig. 2). In
extracts from S. frugiperda Sf9 cells infected with the
recombinant baculovirus (Fig. 2, lane 3), the El protein and
a few additional cellular proteins could be seen; they were
also reactive in wild-type baculovirus-infected cells (Fig. 2,
lane 2).
Lane 4 of Fig. 2 represents the purified recombinant
antigen. In addition to the El and E2 polypeptides, there
exists an immunologically reactive protein (90 to 95 kDa)
that is presumed to be a polyprotein precursor. It has been
reported that the cDNA encoding the spike proteins ofRV is
expressed in recombinant baculovirus-infected Sf9 cells as a
polyprotein, which is processed to form two smaller proteins
that are equivalent to the El and E2 proteins ofRV (20). The
cellular protein, which was reactive with rabbit anti-RV
antibodies, was also detectable by immunoblot analyses.
The antigenic characteristics of the recombinant proteins
were further analyzed by immunoblotting with human RV
antibody-positive sera (Fig. 3). These sera showed reactiv-
ities with the El protein, although the reactions were weak.
Under these conditions, which presumably depend on the
quantity of the proteins, there were no visible reactions with
the polyprotein or the E2 protein.
To study the suitability of the recombinant antigen as a
diagnostic reagent in RV antibody assays, a total of 106
serum samples, including RV antibody-positive and -nega-
tive serum samples, were tested by EIA (Fig. 4). The
correlation of the reactivities between whole-virus antigen
and the recombinant antigen was good (r = 0.861) in this
material that showed similar antigenic activities.
We demonstrated by immunoblotting that, in some cases
of recent RV infection, the IgG antibodies reacted strongly
with the capsid protein and that the reactivities with other
structural proteins remained low (Fig. 5). We tested sera
from patients with recent RV infection and with RV IgM
antibodies with recombinant antigen to determine whether
this difference in reactivities with structural proteins was
visible in EIA. Also, it has been shown that, early after RV
infection, the avidity of IgG antibodies is low and increases
VOL. 29, 1991
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
1880 SEPPANEN ET AL. J. CLIN. MICROBIOL.
0
ti
0
1
S
1
1
*1-
_ 1
1:
0
r=0.861
n=106
0 0
0
*. *
0
S
0
0
00.0
0
* 0
0
0
.
0
* 0
0* . *
0% *g
.0 * 0
*
0
00* 0
0 s
* so %go
0 0
0
Cut-off
50 100 EIU
Whole Virus IgG EIA
FIG. 4. Correlation of the reactivities of the RV IgG antibody-positive and -negative sera between recombinant RV and whole-virus
antigen by EIA. EIU = [(Asample - Arb)/(Apc - Arb)] x 100, where Asample is the mean absorbance of the patient sample, Arb is the mean
absorbance of the reagent blank, and Apc is the mean absorbance of the positive control.
with time (4, 6, 17). However, all of the sera used in this
study were reactive, although the correlation of reactivity
between recombinant and whole-virus antigen (r = 0.690)
was not as close as that with convalescent-phase sera.
Our preliminary results of using the recombinant antigen
in the IgM assays indicated that the reactivities of IgM
antibodies were weak with the recombinant proteins in
indirect EIA (data not shown). We have not tested the
reactivities of the recombinant antigen in an antibody cap-
ture EIA, in which the antigen can be labeled, as has been
done previously with whole-virus antigen (23), or can be
used with labeled anti-RV antibodies. In this type of assay,
the recombinant proteins may be more reactive with IgM
antibodies.
In conclusion, we expressed RV envelope proteins in
recombinant baculovirus-infected lepidopteran insect cells
and purified the proteins by immunoaffinity chromatogra-
phy. Our results demonstrate that their antigenicities in RV
IgG EIA correlate well with those of whole-virus antigen.
Thus, the recombinant proteins have a potential for use in
the routine detection of human RV IgG antibodies.
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FIG. 5. Reactivities of sera from patients with recent RV infec-
tions as determined by immunoblot analyses by using nonreduced
whole-virus antigen. Lane 1, molecular weight markers (in thou-
sands; K); lane 2, reactivities of RV IgG antibodies in serum from a
patient with remote RV infection; lane 3 and 4, reactivities of RV
IgG antibodies in sera from patients with recent RV infections. The
capsid and El proteins are indicated.
.5
c asL
E 150-
100 -
50 -
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
DIAGNOSIS OF RUBELLA IMMUNITY AND RECENT INFECTION 1881
.
0
0
0 -
* 0
0*
S
0
50 100 EIU
Whole Virus IgG EIA
FIG. 6. Correlation of the reactivities of RV IgG antibodies between recombinant and whole-virus antigen in EIA when tested with sera
from patients with a recent RV infection. See the legend to Fig. 4 for the definition of EIU.
ACKNOWLEDGMENTS
We thank Klaus Hedman (Department of Virology, University of
Helsinki) for providing serum samples and Riitta Puranen for
excellent technical assistance.
REFERENCES
1. Bardeletti, G., N. Kessler, and M. Aymard-Henry. 1975. Mor-
phology, biochemical analysis and neuraminidase activity of
rubella virus. Arch. Virol. 49:175-186.
2. Chong, P., and S. Giliam. 1985. Purification of biologically
active rubella virus antigens by immunoaffinity chromatogra-
phy. J. Virol. Methods 10:261-268.
3. Clarke, D. M., T. W. Loo, H. McDonald, and S. Gillam. 1988.
Expression of rubella virus cDNA coding for the structural
proteins. Gene 65:23-30.
4. Enders, G., and F. Knotek. 1989. Rubella IgG total antibody
avidity and IgG subclass-specific antibody avidity assay and
their role in differentiation between primary rubella and rubella
reinfection. Infection 17:218-226.
5. Green, K. Y., and P. H. Dorsett. 1986. Rubella virus antigens:
localization of epitopes involved in hemagglutination and neu-
tralization by using monoclonal antibodies. J. Virol. 57:893-898.
6. Hedman, K., and I. Seppala. 1988. Recent rubella virus infection
indicated by low avidity of specific IgG. J. Clin. Immunol.
8:214-221.
7. Hobman, T. C., M. L. Lundstrom, and S. Gillam. 1990. Proc-
essing and intracellular transport of rubella virus structural
proteins in COS cells. Virology 178:122-133.
8. Ho-Terry, L., and A. Cohen. 1984. The role of glycosylation on
haemagglutination and immunological reactivity of rubella vi-
rus. Arch. Virol. 79:139-146.
9. Ho-Terry, L., G. M. Terry, A. Cohen, and P. Londesborough.
1986. Immunological characterization of the rubella El glyco-
protein. Arch. Virol. 90:145-152.
10. Inoye, S., A. Hasegawa, S. Matsuno, and S. Katow. 1984.
Changes in antibody avidity after virus infections: detection by
an immunosorbent assay in which a mild protein-denaturing
agent is employed. J. Clin. Microbiol. 20:525-529.
11. Katow, S., and A. Sugiura. 1985. Antibody response to individ-
ual rubella virus proteins in congenital and other rubella virus
infections. J. Clin. Microbiol. 21:449-451.
12. Kuroda, K., H. Geyer, R. Geyer, W. Doerfler, and H.-D. Klenk.
1990. The oligosaccharides of influenza virus hemagglutinin
expressed in insect cells by a baculovirus vector. Virology
174:418-429.
13. Laemmli, U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227:680-685.
14. Lozzi, L., M. Rustici, M. Corti, M. G. Cusi, P. E. Valensin, L.
Bracci, A. Santucci, P. Soldani, A. Spreafico, and P. Neri. 1990.
:=I
I
I
r=0.690
n=26
_4 _
caO
c tm
E =
cc m
100 -
50 -
Cut-off
VOL. 29, 1991
I  on
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
1882 SEPPANEN ET AL.
Structure of rubella El glycoprotein epitopes established by
multiple peptide synthesis. Arch. Virol. 110:271-276.
15. Luckow, V. A., and M. D. Summers. 1988. Trends in the
development of baculovirus expression vectors. Bio/Technol-
ogy 6:47-53.
16. Miller, L. K. Baculoviruses as gene expression vectors. Annu.
Rev. Microbiol. 42:177-179.
17. Morgan-Capner, P., and H. I. Thomas. 1988. Serological dis-
tinction between primary rubella and reinfection. Lancet i:1397.
18. Nakhasi, H. L., B. C. Meyer, and T.-Y. Liu. 1986. Rubella virus
cDNA. J. Biol. Chem. 261:16616-16621.
19. Oker-Blom, C., N. Kalkkinen, L. Kaarirainen, and R. F. Petters-
son. 1983. Rubella virus contains one capsid protein and three
envelope glycoproteins, El, E2a, and E2b. J. Virol. 46:964-973.
20. Oker-Blom, C., R. F. Pettersson, and M. D. Summers. 1989.
Baculovirus polyhedrin promoter-directed expression of rubella
virus envelope glycoproteins, El and E2, in Spodoptera fru-
giperda cells. Virology 172:82-91.
21. Partanen, P., H. Seppanen, J. Suni, and A. Vaheri. 1985.
Selective reactivity of antibodies to human immunoglobulins G,
M, and A with rubella virus proteins. J. Clin. Microbiol.
21:800-802.
22. Porterfield, J. S., J. Casals, M. P. Chumakov, S. Y. Gaidamov-
ich, C. Hannoun, I. H. Holmes, M. C. Horzinek, M. Mussgay, N.
Oker-Blom, P. K. Russell, and D. W. Trent. 1987. Togaviridae.
Intervirology 9:129-148.
23. Seppanen, H. 1990. Development of a highly specific and
sensitive rubella immunoglobulin M antibody capture enzyme
immunoassay that uses enzyme-labeled antigen. J. Clin. Micro-
biol. 28:719-723.
24. Terry, G. M., L. Ho-Terry, P. Londesborough, and K. R. Rees.
1988. Localization of the rubella El epitopes. Arch. Virol.
98:189-197.
25. Terry, G. M., L. Ho-Terry, P. Londesborough, and K. R. Rees.
1989. A bio-engineered rubella El antigen. Arch. Virol. 104:63-
75.
26. Thomson, A., G. Davis, J. M. Best, and J. P. Whiteside. 1989.
Growth of rubella virus in a glass bead propagator. J. Virol.
Methods 25:119-122.
27. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedure and some applications. Proc. Nati. Acad. Sci.
USA 76:4350-4354.
28. Vaheri, A., and T. Hovi. 1972. Structural proteins and subunits
of rubella virus. J. Virol. 9:10-16.
29. Vaheri, A., W. D. Sedwick, S. A. Plotkin, and R. Maes. 1965.
Cytopathic effect of rubella virus in BHK21 cells and growth to
high titers in suspension culture. Virology 27:239-241.
30. Waxham, M. N., and J. S. Wolinsky. 1983. Immunochemical
identification of rubella virus hemagglutinin. Virology 126:194-
203.
31. Waxham, M. N., and J. S. Wolinsky. 1985. Detailed immuno-
logic analysis of the structural polypeptides of rubella virus
using monoclonal antibodies. Virology 143:153-165.
J. CLIN. MICROBIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
